Short Interest in The Oncology Institute, Inc. (NASDAQ:TOI) Rises By 193.9%

The Oncology Institute, Inc. (NASDAQ:TOI) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 1,240,000 shares, an increase of 193.9% from the November 15th total of 421,900 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 1,540,000 shares, the short-interest ratio is presently 0.8 days.

Insider Buying and Selling at Oncology Institute

In other news, Director Brad Hively acquired 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were bought at an average cost of $0.17 per share, with a total value of $42,500.00. Following the acquisition, the director now owns 616,753 shares in the company, valued at approximately $104,848.01. This represents a 68.17 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TOI. Tiff Advisory Services LLC lifted its position in Oncology Institute by 235.1% in the 2nd quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock valued at $653,000 after acquiring an additional 995,280 shares in the last quarter. Renaissance Technologies LLC lifted its position in Oncology Institute by 142.3% in the 2nd quarter. Renaissance Technologies LLC now owns 339,400 shares of the company’s stock valued at $156,000 after acquiring an additional 199,300 shares in the last quarter. Finally, HighTower Advisors LLC lifted its position in Oncology Institute by 190.8% in the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after acquiring an additional 53,382 shares in the last quarter. 36.86% of the stock is owned by institutional investors.

Oncology Institute Stock Performance

Shares of NASDAQ TOI remained flat at $0.22 during mid-day trading on Wednesday. The company had a trading volume of 767,103 shares, compared to its average volume of 534,743. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49. Oncology Institute has a one year low of $0.13 and a one year high of $2.50. The company has a market capitalization of $16.62 million, a P/E ratio of -0.28 and a beta of 0.44. The stock has a 50 day moving average of $0.26 and a two-hundred day moving average of $0.37.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.